Bioerodible silicon-based devices for delivery of therapeutic agents
View Patent ↗This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
1. A device comprising a bioerodible porous silicon-based carrier material wherein the carrier material comprises at least one large molecule therapeutic agent disposed in pores of the carrier material, wherein the therapeutic agent is a protein, and either:
a) the pores have an average pore size from about 15 nm to about 40 nm and the therapeutic agent has a molecular weight from about 100,000 to about 200,000 amu, or
b) the pores have an average pore size from about 25 nm to about 40 nm and the therapeutic agent has a molecular radius from about 6 nm to about 8 nm.
2. The device of claim 1 , in which the therapeutic agent is distributed substantially uniformly through pores of the carrier material.
3. The device of claim 1 , wherein the carrier material has a porosity in the range of about 40% to about 80%.
4. The device of claim 1 , wherein the surface area of the carrier material is between 20 and 1000 m 2 /g.
5. The device of claim 1 , wherein the load level of the carrier material is from about 5% to about 50%.
6. The device of claim 1 , further comprising a second therapeutic agent impregnated in the carrier material.
7. A method of preparing a device of claim 1 , comprising contacting a porous silicon-based carrier material with a therapeutic agent.
8. A method of treating or preventing a condition in a patient comprising administering the device of claim 1 to a patient.
9. The method of claim 8 , wherein the device is administered subconjunctivally, intraperitoneally, intramuscularly, intravitreally, subcutaneously, or subretinally.
10. The method of claim 8 , wherein the device releases the drug over the course of 1 day to 12 months.
11. The device of claim 1 , wherein the average pore size is from about 15 nm to about 40 nm and the therapeutic agent has a molecular weight from about 100,000 to about 200,000 amu.
12. The device of claim 1 , wherein the average pore size is from about 25 nm to about 40 nm and the therapeutic agent has a molecular radius from about 6 nm to about 8 nm.
13. The device of claim 1 , wherein the therapeutic agent is bevacizumab.
14. The device of claim 13 , wherein the average pore size of the carrier material is from about 25 nm to 35 nm.
15. The device of claim 13 , wherein the average pore size of the carrier material is about 30 nm.
16. The device of claim 1 , wherein the protein is an antibody.